Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
GSK, Pfizer and RSV
GSK and Pfizer's RSV vaccines to carry warnings of neurological disorder risk
GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing a rare neurological disorder, the U.S. Food Drug Administration said on Tuesday.
GSK, Pfizer RSV shots must warn about rare paralysis risk
Barré for every million doses given.
FDA adds warning to RSV shots from GSK, Pfizer
Barré syndrome, although it said data don’t prove a causal link and affirmed the shots’ benefit outweighs their risks.
RSV vaccines from Pfizer, GSK take another hit with new FDA warning mandate
The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning about the risk of developing Guillain-Barré syndrome (GBS), a rare neurological condition that can cause paralysis.
GSK, Pfizer RSV Shots Required to Carry Guillain-Barré Syndrome Warnings
A post-marketing review by the FDA detected an increased risk of the autoimmune condition in patients inoculated with GSK’s Arexvy and Pfizer’s Abrysvo, prompting the regulator to require adjustments to the vaccines’ labels.
GSK, Pfizer RSV vaccines to carry warnings of GBS, Reuters reports
GSK (GSK) and Pfizer (PFE) vaccines for respiratory syncytial virus, or RSV, will carry warnings that they can increase the risk of developing
Pfizer And GSK's RSV Vaccines Safety Labels Updated, FDA Adds Warning For Rare Neurological Disorder
FDA updates safety labels for Pfizer's Abrysvo and GSK's Arexvy RSV vaccines, citing increased Guillain-Barré syndrome risk. Study estimates 7-9 excess GBS cases per million doses.
FDA requires GSK and Pfizer vaccines to carry rare side effect warnings
Investing.com -- The US Food and Drug Administration (FDA) on Tuesday directed that vaccines for a common respiratory virus developed by GSK and Pfizer (NYSE: PFE) must include warnings about a rare neurological side effect. The vaccines in question are GSK's Arexvy and Pfizer's Abrysvo, designed to combat the respiratory syncytial virus.
Hosted on MSN
3h
Pharma Stock Roundup: FDA Updates for JNJ, GSK, PFE, NVO's Expanded Deal
This week, the FDA granted priority review status to J&J’s JNJ application seeking approval of key pipeline candidate ...
devdiscourse
2d
Healthcare Headlines: From COVID-19 to New Pharmaceutical Ventures
Recent health news includes Donald Trump's consideration of an executive order on gas stoves, Roche's acquisition of Poseida, ...
7h
Alzheimer’s could be diagnosed 10 years earlier after world’s largest blood proteins study
Alzhemier’s disease could be diagnosed up to a decade earlier after the world’s biggest study of proteins is completed. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Sentenced with no penalty
Los Angeles wildfire updates
California fires: How to help
Singer Anita Bryant dies
Kohl's closing 27 stores
'Pizzagate' gunman killed
Vance resigns from Senate
Says ready to meet w/ Putin
Judge scraps Title IX rules
On hedge funds homeownership
Orange Bowl win
Must face defamation suit
Hosts AfD leader on X
Presidential palace attack
1.2M-year-old ice core
La Nina finally arrives
Sworn in as NH governor
Sues over ‘Rust' prosecution
WI triple homicide arrest
Quits climate group
Houthi-hit tanker saved
Mar 9: Canada's PM decision
ACLU sues DeSantis
Yoon's security chief resigns
US settles w/ Johns Hopkins
Wycheck had CTE
Ski patrol strike ends
Earth's hottest year: 2024
Feedback